Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutation
Lung cancer is the sixth leading cause of death worldwide and one of the leading cause of death from malignant tumors. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Epidermal growth factor receptor (EGFR) gene mutation is a common mutation in NSCLC. For advanced NSCLC pa...
Main Authors: | Junxia HUANG, Hong WANG |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2022-03-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.05 |
Similar Items
-
Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?
by: Sviatoslav Chekhun, et al.
Published: (2023-12-01) -
The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
by: Shih-Chieh Chang, et al.
Published: (2011-06-01) -
Baseline anemia predicts a poor prognosis in patients with non-small cell lung cancer with epidermal growth factor receptor mutations: a retrospective study
by: Jingwen Wei, et al.
Published: (2022-10-01) -
Detection and Clinical Significance of Abundance of EGFR Mutation
by: Yi SHAO, et al.
Published: (2017-08-01) -
Progress and prospect of epidermal growth factor receptor tyrosine kinase inhibitor in treatment of non-small cell lung cancer
by: JIANG Hanshui, et al.
Published: (2022-12-01)